Search hospitals > New Jersey > Newark

Newark Beth Israel Medical Center

Claim this profile
Newark, New Jersey 07112
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Leukemia
Conducts research for Lymphoblastic Leukemia-Lymphoma
Conducts research for Lymphoid Leukemia
388 reported clinical trials
20 medical researchers
Photo of Newark Beth Israel Medical Center in NewarkPhoto of Newark Beth Israel Medical Center in NewarkPhoto of Newark Beth Israel Medical Center in Newark

Summary

Newark Beth Israel Medical Center is a medical facility located in Newark, New Jersey. This center is recognized for care of Breast Cancer, Cancer, Leukemia, Lymphoblastic Leukemia-Lymphoma, Lymphoid Leukemia and other specialties. Newark Beth Israel Medical Center is involved with conducting 388 clinical trials across 529 conditions. There are 20 research doctors associated with this hospital, such as Teena Bhatla, Howard S. Hochster, Missak Haigentz, MD, and Patrick M. Boland.

Area of expertise

1Breast Cancer
Global Leader
Newark Beth Israel Medical Center has run 53 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
HER2 positive
2Cancer
Global Leader
Newark Beth Israel Medical Center has run 48 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage I
Stage III

Top PIs

Clinical Trials running at Newark Beth Israel Medical Center

Breast Cancer
Non-Small Cell Lung Cancer
Diffuse Large B-Cell Lymphoma
Lung Cancer
Acute Lymphoblastic Leukemia
Rhabdomyosarcoma
Cancer
Lymphoma
Acute Leukemia
B-Cell Lymphoma
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Image of trial facility.

Tucatinib + Trastuzumab + Pertuzumab

for Breast Cancer

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). In this study, all participants will get either tucatinib or placebo. Participants will be assigned randomly to a group. This is a blinded study, so patients and their doctors will not know which group a participant is in. All participants will also get trastuzumab and pertuzumab. These are 2 drugs used to treat this type of cancer.
Recruiting1 award Phase 311 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Newark Beth Israel Medical Center?
Newark Beth Israel Medical Center is a medical facility located in Newark, New Jersey. This center is recognized for care of Breast Cancer, Cancer, Leukemia, Lymphoblastic Leukemia-Lymphoma, Lymphoid Leukemia and other specialties. Newark Beth Israel Medical Center is involved with conducting 388 clinical trials across 529 conditions. There are 20 research doctors associated with this hospital, such as Teena Bhatla, Howard S. Hochster, Missak Haigentz, MD, and Patrick M. Boland.
Where is Newark Beth Israel Medical Center located?
The Newark Beth Israel Medical Center is located at 201 Lyons Ave, Newark, NJ 07112.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Newark Beth Israel Medical Center, contact the billing department at 973-926-6517. For insurance inquiries, refer to the hospital's phone directory for a dedicated insurance line. Uninsured and underinsured patients meeting specific income and asset criteria may be eligible for the New Jersey Hospital Care Payment Assistance Program (Charity Care).
What insurance does Newark Beth Israel Medical Center accept?
Newark Beth Israel Medical Center, part of RWJBarnabas Health, accepts a wide range of insurance plans including but not limited to Blue Cross/Blue Shield, Commonwealth Care, Harvard Pilgrim Health Care, Neighborhood Health Plan, Mass Health/Medicaid, Medicare, Tufts, and most commercial insurances. They also provide services to patients without insurance. For a detailed list of accepted insurance plans, refer to the RWJBarnabas Health Contracted Health Insurers and Networks list. Note: It's crucial to verify with your physician if they participate in the same insurance plans as the hospital.
What awards or recognition has Newark Beth Israel Medical Center received?
Newark Beth Israel Medical Center is celebrated as one of the World's Best Hospitals by Newsweek for five consecutive years, making it one of seven New Jersey hospitals to achieve this distinction. It has earned the American Heart Association's Get With The Guidelines Gold Award for Heart Failure and Resuscitation. Additionally, it has received the American College of Cardiology's Performance Achievement Award for Cardiac Care.